American listed companies are sincerely seeking innovative ADCs and bispecific antibodies. The specific requirements are as follows:
- Stage: IND, Phase 1 clinical trial
- Molecular entities: ADCs, bispecific antibodies
- Targets: Innovative targets (not competitive, not crowded)
- Rights Interested: Global rights, excluding China rights
- Preferred cooperation model: Licensing
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
Please indicate the project code: BP-20240725-EE-77
We will discuss in detail with you. Thank you!
Contact person: Richard
Phone: 17821449819
WeChat: DrugTimes_BD
Email: BD@drugtimes.cn
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 